Recombinant Factor VIIa for Intracerebral Hemorrhage

Abstract

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy (including evolving and controversial data) for adult intensive care unit patients will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Zachariah Thomas, PharmD at zachariah.thomas@gmail.com or Sandra Kane-Gill, PharmD, MSc, at kanesl@upmc.edu.